Silybin, a new iron-chelating agent

被引:95
|
作者
Borsari, M
Gabbi, C
Ghelfi, F
Grandi, R
Saladini, M
Severi, S
Borella, F
机构
[1] Univ Modena, Dipartimento Chim, I-41100 Modena, Italy
[2] Ist Biochim Italiano, Milan, Italy
关键词
silybin; iron chelator; chronic iron overload; Cooley's anemia;
D O I
10.1016/S0162-0134(01)00198-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Silybin, a natural occurring flavolignan isolated from the fruits of Silibum marianum, has been reported to exert antioxidant and free radical scavenging abilities. It was suggested to act also as an iron chelator. The complexation and protonation equilibria of the ferric complex of this compound have been studied by potentiometric, spectrophotometric and electrochemical techniques. The formation of the complex silybin-Ga(III) in anhydrous DMSO-d6 has been studied by H-1 NMR spectroscopy. Mass spectrometry and infrared spectroscopy on silybin-Fe(III) complex confirm all data obtained by H-1 NMR spectroscopy. The experimental results show that silybin binds Fe(III) even at acidic pH. Different ternary complexes were observed at increasing methoxide ion concentration and their stability constants have been calculated. The results show the possible role of silybin in relation to the chelation therapy of chronic iron overload, as occurs in the treatment of Cooley's anemia. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:123 / 129
页数:7
相关论文
共 50 条
  • [41] IRON-CHELATING ENZYME FROM DUCK ERYTHROCYTES
    YONEYAMA, Y
    SUGITA, Y
    OHYAMA, H
    YOSHIKAWA, H
    BIOCHIMICA ET BIOPHYSICA ACTA, 1962, 62 (02) : 261 - &
  • [42] DEVELOPMENT OF IRON-CHELATING AGENTS FOR CLINICAL USE
    BRITTENHAM, GM
    BLOOD, 1992, 80 (03) : 569 - 574
  • [43] ANTIOXIDANT AND IRON-CHELATING AGENTS IN CEREBRAL VASOSPASM
    LUO, ZY
    HARADA, T
    LONDON, S
    GAJDUSEK, C
    MAYBERG, MR
    NEUROSURGERY, 1995, 37 (06) : 1154 - 1158
  • [44] Clinical studies of iron-chelating treatment in malaria
    Gordeuk, VR
    Biemba, G
    Thuma, PE
    MOLECULAR BIOLOGY OF HEMATOPOIESIS 5, 1996, : 685 - 691
  • [45] Synthesis and characterization of novel iron-chelating agents
    Edenfield, Emily T.
    Whitlock, Christine R.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 231
  • [46] Comparison of cardiac dysfunction in thalassemia major patients using deferoxamine or deferiprone as an iron-chelating agent
    Josep, Rosalina
    Wahidiyat, Pustika Amalia
    Trihono, Partini Pudjiastuti
    Yanuarso, Piprim B.
    PAEDIATRICA INDONESIANA, 2012, 52 (05) : 272 - 279
  • [47] IRON-CHELATING AGENTS AND THE REDUCTIVE REMOVAL OF IRON FROM TRANSFERRIN
    ANKEL, E
    PETERING, DH
    BIOCHEMICAL PHARMACOLOGY, 1980, 29 (12) : 1833 - 1837
  • [48] Immune function in patients with beta thalassaemia receiving the orally active iron-chelating agent deferiprone
    Loebstein, R
    Dalal, I
    NisbetBrown, E
    Berkovitch, M
    Meydan, N
    Andrews, D
    Loubser, MD
    Koren, G
    Roifman, CM
    Olivieri, NF
    BRITISH JOURNAL OF HAEMATOLOGY, 1997, 98 (03) : 597 - 600
  • [49] A STUDY OF THE EFFECTIVENESS OF THE IRON-CHELATING AGENT DEFEROXAMINE AS VASOSPASM PROPHYLAXIS IN A RABBIT MODEL OF SUBARACHNOID HEMORRHAGE
    VOLLMER, DG
    HONGO, K
    OGAWA, H
    TSUKAHARA, T
    KASSELL, NF
    NEUROSURGERY, 1991, 28 (01) : 27 - 32
  • [50] POTENTIATION OF HYDROXYUREA CYTOTOXICITY IN HUMAN CHRONIC MYELOID-LEUKEMIA CELLS BY IRON-CHELATING AGENT
    SATYAMOORTHY, K
    CHITNIS, MP
    BASRUR, VS
    ADVANI, SH
    LEUKEMIA RESEARCH, 1986, 10 (11) : 1327 - 1330